<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207583</url>
  </required_header>
  <id_info>
    <org_study_id>0887X1-4596</org_study_id>
    <secondary_id>B1841011</secondary_id>
    <nct_id>NCT01207583</nct_id>
  </id_info>
  <brief_title>Prevenar (PCV-7) Post-Licensure Safety Study In Russia</brief_title>
  <official_title>Prevenar Post-Licensure Safety Study in Russia: Frequency Of Fever Post Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to monitor the local and/or systemic reactions and compatibility of
      PCV-7 with routine vaccines in the Russian National immunization schedule. Consistent with
      the observational nature of this protocol, Prevenar will be administered as standard of care.

      The aim of this study is to estimate the incidence of febrile reactions more than 38.0
      degrees Celsius, specifically (â‰¥38 to &lt; 39 degrees C; &gt; 39 to &lt; 40 degrees C and &gt; 40 degrees
      C, and the frequency of other local or systemic reactions following vaccination with Prevenar
      (PCV-7) co-administered with other routine childhood vaccines under the conditions of routine
      daily use in the Russian Federation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Febrile Reactions Post-dose 1</measure>
    <time_frame>Day 1 to Day 3 post-dose 1</time_frame>
    <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of greater than or equal to (&gt;=) 38 degrees Celsius (C). Percentage of participants with febrile reaction of &gt;=38 degrees C to less than or equal to (&lt;=) 39 degrees C, &gt;39 degrees C to &lt;=40 degrees C and &gt;40 degrees C were observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Febrile Reactions Post-dose 2</measure>
    <time_frame>Day 1 to Day 3 post-dose 2</time_frame>
    <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C to &lt;=39 degrees C was observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Febrile Reactions Post-dose 3</measure>
    <time_frame>Day 1 to Day 3 post-dose 3</time_frame>
    <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C to &lt;=39 degrees C was observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Febrile Reactions Post-dose 4</measure>
    <time_frame>Day 1 to Day 3 post-dose 4</time_frame>
    <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C was observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Local Reactions Post-dose 1</measure>
    <time_frame>Day 1 to Day 3 post-dose 1</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 centimeters [cm]); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Local Reactions Post-dose 2</measure>
    <time_frame>Day 1 to Day 3 post-dose 2</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Local Reactions Post-dose 3</measure>
    <time_frame>Day 1 to Day 3 post-dose 3</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Local Reactions Post-dose 4</measure>
    <time_frame>Day 1 to Day 3 post-dose 4</time_frame>
    <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Systemic Events Post-dose 1</measure>
    <time_frame>Day 1 to Day 3 post-dose 1</time_frame>
    <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Systemic Events Post-dose 2</measure>
    <time_frame>Day 1 to Day 3 post-dose 2</time_frame>
    <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Systemic Events Post-dose 3</measure>
    <time_frame>Day 1 to Day 3 post-dose 3</time_frame>
    <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pre-Specified Systemic Events Post-dose 4</measure>
    <time_frame>Day 1 to Day 3 post-dose 4</time_frame>
    <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy Children After Vaccination</condition>
  <arm_group>
    <arm_group_label>healthy children after vaccination</arm_group_label>
    <description>healthy children after vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-interventional observational study</intervention_name>
    <description>Non-interventional observational study</description>
    <arm_group_label>healthy children after vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Infants and Children from 3 months to 23 months at enrollment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants eligible for Prevenar vaccination according to the Regulatory approved terms
             of the marketing authorization in the Russian Federation:

          -  Infants from 3 months up to 23 months of age who may benefit from active immunization
             against disease caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F
             and 23F (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media).

          -  Parents or legal guardians willing and able to complete the diary cards.

        Exclusion Criteria:

          -  Hypersensitivity to the active substances or to any of the excipients;

          -  Hypersensitivity to diphtheria toxoid;

          -  Age less than 3 months or greater than or equal to 2 years at enrollment;

          -  Contraindications as listed in the Package Insert / Russian SmPC for either Prevenar
             or for any concomitantly used other vaccines;

          -  Previously vaccinated with 23-valent pneumococcal polysaccharide vaccine;

          -  Prophylactic use of non-steroidal anti-inflammatory medications and/or acetaminophen
             (e.g., paracetamol). However, acetaminophen/paracetamol may be administered for
             treatment of fever, pain, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russian State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Academy of Medical Sciences</name>
      <address>
        <city>Moscow</city>
        <zip>119296</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Childhood Infections</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Children's Clinical Hospital #8</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620085</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0887X1-4596&amp;StudyName=Prevenar%20%28PCV-7%29%20Post-Licensure%20Safety%20Study%20In%20Russia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2010</study_first_submitted>
  <study_first_submitted_qc>September 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <results_first_submitted>July 26, 2012</results_first_submitted>
  <results_first_submitted_qc>July 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2012</results_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>infant</keyword>
  <keyword>healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primary Cohort (3-6 Months)</title>
          <description>Participants in the age group 3-6 months received 4 doses (Dose 1, Dose 2, Dose 3 and Dose 4) of 7-valent pneumococcal conjugate vaccine (PCV7) as standard care as per the Summary of Product Characteristics (SmPC).</description>
        </group>
        <group group_id="P2">
          <title>Catch-up Cohort (7-11 Months)</title>
          <description>Participants in the age group 7-11 months received 3 doses (Dose 1, Dose 2 and Dose 3) of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="P3">
          <title>Catch-up Cohort (12-23 Months)</title>
          <description>Participants in the age group 12-23 months received 2 doses (Dose 1 and Dose 2) of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Dose 4</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant failed to return</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary Cohort (3-6 Months)</title>
          <description>Participants in the age group 3-6 months received 4 doses (Dose 1, Dose 2, Dose 3 and Dose 4) of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="B2">
          <title>Catch-up Cohort (7-11 Months)</title>
          <description>Participants in the age group 7-11 months received 3 doses (Dose 1, Dose 2 and Dose 3) of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="B3">
          <title>Catch-up Cohort (12-23 Months)</title>
          <description>Participants in the age group 12-23 months received 2 doses (Dose 1 and Dose 2) of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>3 to 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 to 11 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 to 23 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Febrile Reactions Post-dose 1</title>
        <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of greater than or equal to (&gt;=) 38 degrees Celsius (C). Percentage of participants with febrile reaction of &gt;=38 degrees C to less than or equal to (&lt;=) 39 degrees C, &gt;39 degrees C to &lt;=40 degrees C and &gt;40 degrees C were observed.</description>
        <time_frame>Day 1 to Day 3 post-dose 1</time_frame>
        <population>Safety set (post-dose 1) population included all participants who received Dose 1 and who had safety follow-up data following Dose 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O3">
            <title>Catch-up Cohort (12-23 Months)</title>
            <description>Participants in the age group 12-23 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Febrile Reactions Post-dose 1</title>
          <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of greater than or equal to (&gt;=) 38 degrees Celsius (C). Percentage of participants with febrile reaction of &gt;=38 degrees C to less than or equal to (&lt;=) 39 degrees C, &gt;39 degrees C to &lt;=40 degrees C and &gt;40 degrees C were observed.</description>
          <population>Safety set (post-dose 1) population included all participants who received Dose 1 and who had safety follow-up data following Dose 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>38 to 39 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="4.0" upper_limit="39.9"/>
                    <measurement group_id="O2" value="16.1" lower_limit="7.1" upper_limit="32.6"/>
                    <measurement group_id="O3" value="1.8" lower_limit="0.3" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;39 to 40 degrees C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="21.5"/>
                    <measurement group_id="O2" value="3.2" lower_limit="0.6" upper_limit="16.2"/>
                    <measurement group_id="O3" value="3.6" lower_limit="1.0" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Febrile Reactions Post-dose 2</title>
        <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C to &lt;=39 degrees C was observed.</description>
        <time_frame>Day 1 to Day 3 post-dose 2</time_frame>
        <population>Safety set (post-dose 2) population included all participants who received Dose 2 and who had safety follow-up data following Dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O3">
            <title>Catch-up Cohort (12-23 Months)</title>
            <description>Participants in the age group 12-23 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Febrile Reactions Post-dose 2</title>
          <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C to &lt;=39 degrees C was observed.</description>
          <population>Safety set (post-dose 2) population included all participants who received Dose 2 and who had safety follow-up data following Dose 2.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="8.2" upper_limit="50.3"/>
                    <measurement group_id="O2" value="10.3" lower_limit="3.6" upper_limit="26.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Febrile Reactions Post-dose 3</title>
        <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C to &lt;=39 degrees C was observed.</description>
        <time_frame>Day 1 to Day 3 post-dose 3</time_frame>
        <population>Safety set (post-dose 3) population included all participants who received Dose 3 and who had safety follow-up data following Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Febrile Reactions Post-dose 3</title>
          <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C to &lt;=39 degrees C was observed.</description>
          <population>Safety set (post-dose 3) population included all participants who received Dose 3 and who had safety follow-up data following Dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="4.3" upper_limit="42.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Febrile Reactions Post-dose 4</title>
        <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C was observed.</description>
        <time_frame>Day 1 to Day 3 post-dose 4</time_frame>
        <population>Safety set (post-dose 4) population included all participants who received Dose 4 and who had safety follow-up data following Dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 4 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Febrile Reactions Post-dose 4</title>
          <description>Febrile reactions were defined as reactions which causes a rise in body temperature following vaccination in children. Fever was defined as a temperature of &gt;=38 degrees C. Percentage of participants with febrile reaction of &gt;=38 degrees C was observed.</description>
          <population>Safety set (post-dose 4) population included all participants who received Dose 4 and who had safety follow-up data following Dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 1</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 centimeters [cm]); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
        <time_frame>Day 1 to Day 3 post-dose 1</time_frame>
        <population>Safety set (post-dose 1) population included all participants who received Dose 1 and who had safety follow-up data following Dose 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O3">
            <title>Catch-up Cohort (12-23 Months)</title>
            <description>Participants in the age group 12-23 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 1</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 centimeters [cm]); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
          <population>Safety set (post-dose 1) population included all participants who received Dose 1 and who had safety follow-up data following Dose 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site hematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site warmth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 2</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
        <time_frame>Day 1 to Day 3 post-dose 2</time_frame>
        <population>Safety set (post-dose 2) population included all participants who received Dose 2 and who had safety follow-up data following Dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O3">
            <title>Catch-up Cohort (12-23 Months)</title>
            <description>Participants in the age group 12-23 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 2</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
          <population>Safety set (post-dose 2) population included all participants who received Dose 2 and who had safety follow-up data following Dose 2.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site hemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 3</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
        <time_frame>Day 1 to Day 3 post-dose 3</time_frame>
        <population>Safety set (post-dose 3) population included all participants who received Dose 3 and who had safety follow-up data following Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 3</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
          <population>Safety set (post-dose 3) population included all participants who received Dose 3 and who had safety follow-up data following Dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 4</title>
        <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
        <time_frame>Day 1 to Day 3 post-dose 4</time_frame>
        <population>Safety set (post-dose 4) population included all participants who received Dose 4 and who had safety follow-up data following Dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 4 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Local Reactions Post-dose 4</title>
          <description>Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and redness were scaled as Any (induration or redness present); Mild (&lt;2.5 cm); Moderate (&gt;=2.5 cm to &lt;5.0 cm); Severe (&gt;=5.0 cm). Participants may be represented in more than 1 category. Solicited local reactions included redness, swelling and tenderness while unsolicited local reactions included injection site hematoma, injection site hemorrhage, injection site induration and injection site warmth.</description>
          <population>Safety set (post-dose 4) population included all participants who received Dose 4 and who had safety follow-up data following Dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 1</title>
        <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 to Day 3 post-dose 1</time_frame>
        <population>Safety set (post-dose 1) population included all participants who received Dose 1 and who had safety follow-up data following Dose 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O3">
            <title>Catch-up Cohort (12-23 Months)</title>
            <description>Participants in the age group 12-23 months received Dose 1 of PCV7 vaccines as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 1</title>
          <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety set (post-dose 1) population included all participants who received Dose 1 and who had safety follow-up data following Dose 1.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restless sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="32.3"/>
                    <measurement group_id="O3" value="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="25.8"/>
                    <measurement group_id="O3" value="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="19.4"/>
                    <measurement group_id="O3" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.5"/>
                    <measurement group_id="O3" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 2</title>
        <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 to Day 3 post-dose 2</time_frame>
        <population>Safety set (post-dose 2) population included all participants who received Dose 2 and who had safety follow-up data following Dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O3">
            <title>Catch-up Cohort (12-23 Months)</title>
            <description>Participants in the age group 12-23 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 2</title>
          <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety set (post-dose 2) population included all participants who received Dose 2 and who had safety follow-up data following Dose 2.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restless sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="24.1"/>
                    <measurement group_id="O3" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="20.7"/>
                    <measurement group_id="O3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 3</title>
        <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 to Day 3 post-dose 3</time_frame>
        <population>Safety set (post-dose 3) population included all participants who received Dose 3 and who had safety follow-up data following Dose 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
          <group group_id="O2">
            <title>Catch-up Cohort (7-11 Months)</title>
            <description>Participants in the age group 7-11 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 3</title>
          <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety set (post-dose 3) population included all participants who received Dose 3 and who had safety follow-up data following Dose 3.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Restless sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual fussiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 4</title>
        <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
        <time_frame>Day 1 to Day 3 post-dose 4</time_frame>
        <population>Safety set (post-dose 4) population included all participants who received Dose 4 and who had safety follow-up data following Dose 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Cohort (3-6 Months)</title>
            <description>Participants in the age group 3-6 months received Dose 4 of PCV7 vaccine as standard care as per the SmPC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-Specified Systemic Events Post-dose 4</title>
          <description>Systemic events (any fever &gt;=38 degrees C, decreased appetite, diarrhea, restless sleep, unusual crying, unusual fussiness, unusual irritability, and vomiting) were reported using an electronic diary. Participants may be represented in more than 1 category.</description>
          <population>Safety set (post-dose 4) population included all participants who received Dose 4 and who had safety follow-up data following Dose 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Restless sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unusual irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose 1 (Primary Cohort [3-6 Months])</title>
          <description>Participants in the age group 3-6 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E2">
          <title>Dose 2 (Primary Cohort [3-6 Months])</title>
          <description>Participants in the age group 3-6 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E3">
          <title>Dose 3 (Primary Cohort [3-6 Months])</title>
          <description>Participants in the age group 3-6 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E4">
          <title>Dose 4 (Primary Cohort [3-6 Months])</title>
          <description>Participants in the age group 3-6 months received Dose 4 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E5">
          <title>Dose 1 (Catch-up Cohort [7-11 Months])</title>
          <description>Participants in the age group 7-11 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E6">
          <title>Dose 2 (Catch-up Cohort [7-11 Months])</title>
          <description>Participants in the age group 7-11 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E7">
          <title>Dose 3 (Catch-up Cohort [7-11 Months])</title>
          <description>Participants in the age group 7-11 months received Dose 3 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E8">
          <title>Dose 1 (Catch-up Cohort [12-23 Months])</title>
          <description>Participants in the age group 12-23 months received Dose 1 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
        <group group_id="E9">
          <title>Dose 2 (Catch-up Cohort [12-23 Months])</title>
          <description>Participants in the age group 12-23 months received Dose 2 of PCV7 vaccine as standard care as per the SmPC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Disbacteriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Injection site haematoma</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Injection site haemorrhage</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Injection site warmth</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Diarrhea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Restless sleep</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Unusual crying</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Unusual fussiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Unusual irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Systemic events">Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Local reactions">Tenderness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

